Personalizing treatment for chronic lymphocytic leukemia.

about

Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia.

P2860

Q36006445-2EB2283F-BC90-4509-B53E-0F0A4DAFDB5D Q37742056-DDC2A4CC-9A49-4B8E-8F7F-9F8A5DFADF90

P2860

Personalizing treatment for chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q54612791

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Personalizing treatment for chronic lymphocytic leukemia.

@en

Personalizing treatment for chronic lymphocytic leukemia.

@nl

type

Item

label

Personalizing treatment for chronic lymphocytic leukemia.

@en

Personalizing treatment for chronic lymphocytic leukemia.

@nl

prefLabel

Personalizing treatment for chronic lymphocytic leukemia.

@en

Personalizing treatment for chronic lymphocytic leukemia.

@nl

P1476

Personalizing treatment for chronic lymphocytic leukemia.

@en

P2093

Pau Abrisqueta

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Genomic aberrations and survival in chronic lymphocytic leukemia

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Measuring comorbidity in older cancer patients.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

P304

27-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EHM.10.84

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marta Crespo

F Bosch

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21322776

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

Personalizing treatment for chronic lymphocytic leukemia.

about

P2860

P2860

Personalizing treatment for chronic lymphocytic leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921